Skip to main content
Premium Trial:

Request an Annual Quote

Manipulation Concerns Raised

A law firm has informed the US Food and Drug Administration that a regulatory filing from a company developing an Alzheimer's disease treatment may include data showing signs of manipulation, Retraction Watch reports.

The firm, Labaton Sucharow, which Retraction Watch notes is known for filing shareholder suits, submitted a citizen's petition to the FDA regarding Cassava Sciences' simulfilam. In the petition, the firm says its clients have "grave concerns about the quality and integrity of the laboratory-based studies surrounding this drug candidate and supporting the claims for its efficacy." In particular, the petition notes anomalies with western blot images in publications from City University of New York's Hoau-Yan Wang and Cassava's Lindsay Burns supporting the filing as well as the methodology used in post-mortem brain analyses, and more.

In a statement, Cassava says the claims are "false and misleading."

Retraction Watch notes that commenters on PubPeer have now raised concerns regarding other studies from Wang and Burns. In addition, Labaton Sucharow recommends that FDA audit the supporting work and pause ongoing simulfilam trials, it adds.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.